FDA approves Merus’ Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million.
Latest Ratings for MRUS
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | BMO Capital | Initiates Coverage On | Outperform | |
| Feb 2022 | Needham | Initiates Coverage On | Buy | |
| Nov 2021 | HC Wainwright & Co. | Maintains | Buy |
